February 27, 2026 · Form 4 insider transaction
Kewalramani Reshma sold 5,995 shares of Vertex Pharmaceuticals Incorporated at $496.16 per share, a transaction worth $2.97M. The trade was recorded as open-market sale under a pre-scheduled Rule 10b5-1 plan and disclosed on an SEC Form 4, filed 4 days after the transaction.
Transaction made pursuant to Dr. Kewalramani's company approved trading plan under Rule 10b5-1, which was entered into on 11/17/2025.; Dr. Kewalramani undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price.; Open market sales reported on this line occurred at a weighted average price of $496.16 (range $495.79 to $496.74).